Reed Smith LLP acted as Aptorum Group’s legal advisor and listing agent.
Aptorum Group Limited (Nasdaq:APM) announced that its Class A Ordinary Shares has commenced trading on the Professional Compartment of Euronext in Paris under the Euronext ticker symbol “APM” and ISIN Code: KYG6096M1069. Aptorum Group’s Class A Ordinary Shares continues to be listed on the Nasdaq Global Market under the symbol APM.
The company did not issue any additional shares. Aptorum is believed to be the first biotech company to have achieved this sort of cross-listing.
BNP Paribas Securities Services acted as Aptorum Group’s trading agent.
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®.
The Reed Smith team that advised Aptorum on the listing was led by Paris based partner Guilain Hippolyte (Picture) and associate Lucie Guegan. They were supported by London based partner James Wilkinson and associate Fiona McFarlane, and New York based partner Gerry DiFiore and associate Sheran Sharafi.
Law Firms: Reed Smith;
Clients: Aptorum Group;